These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38247798)

  • 1. Tissue-Predisposition to Cancer Driver Mutations.
    Peters L; Venkatachalam A; Ben-Neriah Y
    Cells; 2024 Jan; 13(2):. PubMed ID: 38247798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The structure of the hematopoietic system can explain chronic myeloid leukemia progression.
    Pérez-Jiménez M; Derényi I; Szöllősi GJ
    Sci Rep; 2023 Apr; 13(1):5411. PubMed ID: 37012292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
    Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H
    Lancet Haematol; 2019 May; 6(5):e276-e284. PubMed ID: 31036317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia.
    Hasanova A; Asadov C; Karimova N; Shirinova A; Aliyeva G; Alimirzoyeva Z
    Pathol Oncol Res; 2023; 29():1611518. PubMed ID: 38188610
    [No Abstract]   [Full Text] [Related]  

  • 5. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
    Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
    Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.
    Razga F; Jurcek T; Zackova D; Dvorakova D; Toskova M; Jeziskova I; Mayer J; Racil Z
    Mol Diagn Ther; 2012 Aug; 16(4):251-9. PubMed ID: 22873741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competitive evolved sub-clonal BCR::ABL1 and novel MSI2::PC fusion genes in myelodysplastic syndrome with isolated del(5q).
    Zhang Y; Liu Y; Wang T; Wang H; Chen X; Cao P; Ma X; Liu M; Xu P; Bi H; Pan J; Jiang Y; Li X; Wang W; Liu H
    Hematol Oncol; 2023 Feb; 41(1):178-181. PubMed ID: 36301018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
    BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer.
    Ouerhani S; Bougatef K; Soltani I; Elgaaied AB; Abbes S; Menif S
    Mol Biol Rep; 2013 Jun; 40(6):4109-14. PubMed ID: 23640097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation.
    Tachibana T; Kondo T; Uchida N; Doki N; Takada S; Takahashi S; Yano S; Mori T; Kohno A; Kimura T; Fukuda T; Atsuta Y; Nagamura-Inoue T;
    Transplant Cell Ther; 2022 Jun; 28(6):321.e1-321.e8. PubMed ID: 35296447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular
    Marin AM; Wosniaki DK; Sanchuki HBS; Munhoz EC; Nardin JM; Soares GS; Espinace DC; de Holanda Farias JS; Veroneze B; Becker LF; Costa GL; Beltrame OC; de Oliveira JC; Cambri G; Zanette DL; Aoki MN
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
    Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?
    Shanmuganathan N; Branford S
    Curr Hematol Malig Rep; 2019 Dec; 14(6):501-506. PubMed ID: 31696382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.
    Boddu P; Chihara D; Masarova L; Pemmaraju N; Patel KP; Verstovsek S
    Ann Hematol; 2018 Nov; 97(11):2071-2080. PubMed ID: 29951914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.
    Ryu J; Chu D; Park B; Kim M; Cho YU; Hwang SH; Jang S; Seo EJ; Lee JH; Park CJ
    Lab Med; 2022 Nov; 53(6):e140-e144. PubMed ID: 35243502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors.
    Shojaei M; Rezvani H; Azarkeivan A; Poopak B
    Lab Med; 2021 Mar; 52(2):158-167. PubMed ID: 32821940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
    Cayuela JM; Chomel JC; Coiteux V; Dulucq S; Escoffre-Barbe M; Etancelin P; Etienne G; Hayette S; Millot F; Nibourel O; Nicolini FE; Réa D;
    Bull Cancer; 2020 Jan; 107(1):113-128. PubMed ID: 31353136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
    Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
    Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients.
    Park H; Kim I; Kim HJ; Shin DY; Lee SY; Kwon OH; Kim DY; Lee KH; Ahn JS; Park J; Sohn SK; Lee JO; Cheong JW; Kim KH; Kim HG; Kim H; Lee YJ; Nam SH; Do YR; Park SG; Park SK; Bae SH; Song HH; Oh D; Jung CW; Park S
    Leuk Res; 2021 Dec; 111():106728. PubMed ID: 34673444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.